TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Use of a High Density Mapping System to Complete Wide Area Circumferential Ablation of the Pulmonary Veins and Avoid Ostial Segmental Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ECG documented AF~* Listed for AF ablation by referring physician~* Planned ablation includes a first-time PVI.~* Patient signed informed consent form~Exclusion Criteria:~* Age \<18 or \>80~* LA diameter \>60mm~* AF secondary to transient correctible abnormalits (e.g. electrolyte imbalance, thyrotoxicosis, recent infective or inflammatory process)~* Intra-atrial thrombus or tumour~* Renal failure requiring haemodialysis~* Heart failure with NYHA III-IV or EF\<35%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group A - Standard Care (Type: ACTIVE_COMPARATOR): The operator will attempt to complete the WACA lesion set using standard techniques. These include ablating any obvious gaps in the lesion set, ablating at the WACA line in a location radial to the earliest PV signal measured by the Orion catheter situated within the PV, and guided by amplitude and dV/dt of signals along the WACA lesion set measured using the mapping catheter. If this fails the operator will resort to OSA as per their usual practice.
- Group B - Rhythmia mapping (Type: EXPERIMENTAL): The operator will form Rhythmia maps focussing on the region of the WACA line surrounding the non-isolated vein(s) whilst pacing from CS. This will be used as a means of targeting RF ablation to gaps in the WACA line (in addition to use of standard observation of signals as per group A). If this fails then the operator will resort to OSA as per their usual practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Procalcitonin in Fever of Unknown Etiology

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. All hospitalized patients admitted to general medical or GRM wards with fever and no obvious source of infection, and~2. remain febrile after 72 hours of empiric, antimicrobial therapy, and~3. initial blood cultures are negative.~Exclusion Criteria:~1. Patients with clinically suspected infection (strongly suggestive symptoms, signs or laboratory/imaging studies) such as pneumonia, urinary tract infection, meningitis, endocarditis, skin and soft tissue infection, etc.~2. Confirmed bacterial, viral or fungal infection (positive stain, culture or serology from appropriate clinical specimen).~3. Hypotension (systolic blood pressure \<90mmHg)~4. Respiratory failure (oxygen requirement \> 4L/min via nasal canula)~5. Patients admitted to intensive care unit.~6. Severely immunocompromised patients: (febrile neutropenia, HIV infection with CD4 count \< 200, immuno-suppressive therapy).~7. Patients younger than 21.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intestinal Mesenchymal Stem Stells and Inflammatory Bowel Diseases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* For IBD patients :~  * Age between 18 and 75 year old~ * Diagnosis of Crohn's disease or ulcertaive colitis according to internationla guidelines~ * Endoscopically active disease~ * Indication for colonoscopy or intestinal resection according to standard of care~ * Written inform consent~* For control patients :~  * Age between 18 and 75 year old~ * Indication for screening colonoscopy for irritable bowel syndrome, diverticulum or colorectal cancer surveillance according to standard of care~ * Indication for intestinal resection for diverticulum or colorectal cancer according to standard of care~ * Written inform consent~Exclusion criteria:~* For IBD patients :~  * Active intestinal infection~ * Confirmed intestinal parasitosis~ * Intestinal stoma~* For control patients :~  * Active intestinal infection~ * Confirmed intestinal parasitosis~ * Intestinal inflammation at colonoscopy~ * Chronic intestinal inflammation on biopsies~ * Absence of healthy tissue on surgical specimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Crohn's disease patient group (Type: OTHER): Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
- Ulcerative colitis patient group (Type: OTHER): Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
- Control group (Type: OTHER): Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: STandardized Ultra-conservative Or Physician-directed ICD Programming for Continuous Flow LVAD Support

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-existing ICD~* LVAD placement~Exclusion Criteria:~* Non-functional ICD system~* Uncontrolled ventricular arrhythmias within 7 days of enrollment (defined as VT/VF \>30 seconds and/or causing hemodynamic instability and/or symptoms of pre-syncope or syncope)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultra-conservative ICD programming (Type: EXPERIMENTAL): Single VF zone programming strategy with maximal detection extension to avoid ICD shock delivery with monitoring-only VT detection zones
- Standard programming (physician discretion) (Type: NO_INTERVENTION): Usual care ICD programming, which is historically unchanged from ICD programming pre-LVAD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Ankle Foot Orthoses on Gait Efficiency in Children With Acute Lymphoblastic Leukemia and Foot Drop

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Research participant is diagnosed with childhood ALL and currently being treated on the TOTAL XVI protocol at St. Jude Children's Research Hospital (SJCRH)~2. Research participant is from 6 to 18 years of age at the time of the scheduled evaluation~3. Research participant has chemotherapy-induced peripheral neuropathy resulting in foot drop~4. Research participant will be receiving AFO~5. Research participant has a hemoglobin level greater than 8 g/dL and a platelet count above 50 x 109/L~Exclusion Criteria:~1. Participant has Down Syndrome or other known congenital developmental delays~2. Participant has a platelet count lower than 50 x 109/L and a hemoglobin level less than 8 g/dL~3. Participant has a lower extremity amputation, congenital deformity of the lower limb or an acute fracture of the lower limb~4. Participant has symptomatic osteonecrosis in the lower extremities

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Group One (Type: OTHER): Group one will take a six minute walk test with AFO device, and after a rest of fifteen minutes, they will take another six minute walk test without AFO, with similar speed to the previous test.
- Group Two (Type: OTHER): Group two will take a six minute walk test without AFO device, and after a rest of fifteen minutes, they will take another six minute walk test with AFO, with similar speed to the previous test.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-Patients 18 years of age and older presenting to the Stanford Preoperative Evaluation Clinic prior to elective orthopedic surgical procedures or elective vascular surgical procedures not involving the abdominal aorta or carotid arteries.~Exclusion Criteria:~Patients will be excluded from participation if they have one or more of the following conditions:~1. Evidence of active local or systemic infection as demonstrated by fever, leukocytosis (white blood cell count \> 11,000/ul), productive cough, new infiltrate on chest x-ray, or purulent drainage from any source~2. End-stage renal disease~3. A history of diabetic neuropathy~4. A malignancy other than basal cell carcinoma of the skin or in situ carcinoma of the cervix within the previous 5 years~5. Leukopenia (white blood cell count \< 2,000/ul)~6. Thrombocytopenia (platelet count \< 100,000/ul)~7. Abnormal liver function test result (aspartate aminotransferase or alanine aminotransferase level ≥1.5-fold the upper limit of normal)~8. A history or infection with tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus~9. Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: ACTIVE_COMPARATOR): Two subcutaneous injections of anakinra (IL-1ra) were given, the first one hour prior to surgery and the second 24 hours after surgery.
- Saline injection (Type: PLACEBO_COMPARATOR): Two subcutaneous injections of normal saline (same volume as the anakinra group injection) were given, the first one hour prior to surgery and the second 24 hours after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Central Compartment Neck Dissection With Thyroidectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Indeterminate or benign pathology on fine needle aspirate biopsy~* Scheduled to undergo total or hemi-thyroidectomy~* \> 18 years old~Exclusion Criteria:~* Previous thyroid surgery~* Previous neck surgery in field of thyroidectomy~* Previous neck irradiation~* Pre-operative hypocalcemia or hypoparathyroidism~* Biopsy suggestive of thyroid cancer~* Neck nodes suspicious for or with known cancer~* Pre-operative vocal cord dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Total Thyroidectomy - CLND (Type: ACTIVE_COMPARATOR): Total thyroidectomy without central lymph node dissection.
- Total Thyroidectomy +CLND (Type: EXPERIMENTAL): Total thyroidectomy with central lymph node dissection.
- Hemi-thyroidectomy + CLND (Type: EXPERIMENTAL): Hemi-thyroidectomy with central lymph node dissection.
- Hemi-thyroidectomy - CLND (Type: ACTIVE_COMPARATOR): Hemi-thyroidectomy without central lymph node dissection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Randomized Trial of Early Versus Late Tracheostomy in Trauma Patients With Severe Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* TBI defined as penetrating or blunt brain injury including 1)subarachnoid hemorrhage, 2)subdural hemorrhage, 3) epidural hemorrhage, 4)brain contusion, 5)diffuse axonal injury~* mechanically ventilated by endotracheal intubation~* projected to need ventilation support for more than 14 days according to: GCS measured in field less than or equal to 8 and a GCS on day 3 which remains less than or equal to 8~* informed consent obtained from patient or legal representative~Exclusion Criteria:~* less than 18 years of age~* projected to need ventilation support for less than 14 days~* anatomical deformity of the neck, including thyromegaly and cervical tumors~* previous tracheostomy~* uncontrolled coagulopathy~* existence of platelet count less than 50,000/mm2~* anti-platelet agents~* clinical evidence of ongoing infection at the proposed tracheostomy site as per physician~* mechanical ventilation with a positive end-expiratory pressure greater than 12 cm H20~* intubated more than 72 hours~* patient has undergone cricothyroidotomy~* cricoid cartilage, trachea, or sternal notch not palpable with neck in position

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Early conversion from endotracheal intubation to percutaneous tracheostomy for ventilator support of trauma patients with severe brain injury
- 2 (Type: ACTIVE_COMPARATOR): Conventional conversion from endotracheal intubation to percutaneous tracheostomy for ventilator support of trauma patients with severe brain injury

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of a Psychological Intervention in Patients Undergoing Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Planned unilateral total knee arthroplasty due to gonarthrosis~* Giving consent to participate~Exclusion Criteria:~* Inability to write and read~* Cognitive deficit (assessed by MMSE)~* Revision TKA~* Bilateral TKA~* TKA for reasons other than gonarthrosis (fracture, malignancy or infection)~* Psychiatric or neurological deficit (e.g. Schizophrenia or Alzheimers')~* Diagnosis of rheumatoid arthritis, Psoriatic arthritis, Systemic lupus erythematosus, Anquilosant spondylitis or other severe disease~* Contralateral hip or knee arthroplasty in the previous 6 months~* Planned contralateral hip or knee arthroplasty in the next 6 months

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Group (PNE+HyP) (Type: EXPERIMENTAL): Patients in this group will have 3 pre-surgical + 1 (or 2) reinforcement sessions in adition to standard TKA care. These interventions are based on Pain Neuroscience Education and Hypnosis and delivered according to standardized scripts.
- Control Group (Type: NO_INTERVENTION): No intervention / Standard care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pain in America: A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are new to a discussion about the common methods of managing musculoskeletal pain, over the age of 18, native English speakers~Exclusion Criteria:~* Patient with a previous orthopaedic surgery or musculoskeletal pain consultation, patients without the capacity to give consent, chronic narcotic users. Patients with a severe mental, visual, auditory or tactile impairment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): This group will receive a 10 minute discussion
- Intervention (Type: ACTIVE_COMPARATOR): This group will receive a 10 minute standardized discussion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Timing of Hypertonic Saline Inhalation Relative to Airways Clearance in Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients with a documented diagnosis of CF aged ≥18 years.~2. Written informed consent.~3. At least day 10 - 14 of IV antibiotic therapy during a hospital admission for a pulmonary exacerbation.~4. Patients must be able to perform acceptable spirometric manoeuvres, according to the American Thoracic Society/ERS (ATS/ERS) standards (Miller, Hankinson et. al. 2005).~5. Patient with an FEV1% predicted of ≥ 40%predicted (Stanojevic, Wade et al. 2008).~6. Patients who are productive of sputum from screening visit to study visit 1 (≥10g over 24 hours).~7. Patients who have been prescribed HTS (Nebusal 7%) and have successfully completed a challenge test.~8. Any other chronic medication must have commenced therapy 4 weeks prior to screening and be willing to continue this therapy for the entire duration of the study.~Exclusion Criteria:~1. Day 1-9 of IV antibiotic therapy during a hospital admission.~2. Patients who are colonized with Burkholderia cepacia complex.~3. Patient who are HTS naive.~4. Patients who have an intolerance to HTS.~5. Patients who are currently participating in another study or have participated in another study with an investigational drug within one month of screening.~6. Clinically significant disease or medical condition other than CF or CF-related conditions that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.~   -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ACTs after HTS inhalation: (Type: ACTIVE_COMPARATOR): ACTs after HTS inhalation: Patients will take a bronchodilator (Salbutamol, 2 puffs) wait 15 minutes, and then take a single inhalation (4 mls) of 7% HTS (Nebusal™) via updraft nebulizer (Portex) (approximately 20 minutes) immediately followed by an airways clearance session of 10 supervised cycles of Active Cycle of Breathing Technique (ACBT) using the acapella® (approximately 20 minutes).
- ACTs during HTS inhalation (Type: ACTIVE_COMPARATOR): ACTs during HTS inhalation: Patients take a bronchodilator (Salbutamol, 2 puffs), wait 15 minutes, and then take a single inhalation (4mls) of 7% HTS (Nebusal™) through the acapella® duet (with portex updraft nebulizer attached) device. During inhalation, an airways clearance session of 10 supervised cycles of ACBT using the acapella® will be carried out (approximately 20 minutes).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Severity Postoperative Pain Prediction

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy ASA physical status class 1 or 2~* Aged 18 years or above~* Pregnant with intrauterine pregnancy of at least 36 weeks for cesarean sections~Exclusion Criteria:~* ASA \>3~* \< 36 weeks for Cesarean Section~* \< 18 years of age

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Elective Cesarean Sections-this portion completed
- 3 (Type: None): Any in-patient gynecologic procedure- this portion completed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Pregnancy Outcomes in Good Prognosis Patients Between Fresh and 'Freeze-All' Single Blastocyst Transfers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First IVF cycle~* Normal ovarian reserve parameters (antral follicle count \> 12, follicle stimulating hormone (FSH) \< 10 IU/L, AMH (if measured) \> 15 pmol/L)~* Infertility cause due to tubal factor, male factor with ejaculated sperm or unexplained~* 3 or more fresh transfer or cryopreservation-quality blastocysts on day 5 post-oocyte-retrieval~* GnRH antagonist or long GnRH agonist cycles~Exclusion Criteria:~* Evidence of (or evidence for significant risk of) ovarian hyperstimulation syndrome (OHSS) on post-oocyte-retrieval day 5 (in which the standard protocol is not to perform a fresh embryo transfer, but rather to freeze all blastocysts for future frozen embryo transfers).~* Use of a gonadotropin releasing hormone (GnRH) agonist trigger for ovulation and resulting intensive luteal phase support protocol.~* Women requiring automatic freeze-all approaches (such as for pre-implantation genetic testing or cryopreservation for fertility preservation).~* Female infertility causes that may adversely affect implantation, such as severe endometriosis, fibroids, mullerian abnormalities, or prior uterine procedures resulting in a potentially compromised endometrial cavity.~* In-vitro maturation of oocytes~* Oocyte donation cycles

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Freeze-All Protocol (Type: EXPERIMENTAL): Participants freezing all good quality embryos, with subsequent frozen embryo transfer of best quality blastocyst.
- Fresh Protocol (Type: ACTIVE_COMPARATOR): Participants receiving fresh embryo transfer of best quality blastocyst and freezing of all good quality supernumerary embryos.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues